Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy

CAR-T Cell Therapy in B cell Non-Hodgkin Lymphomas

(2019) Adam Levin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Toxicities of CD19 CAR-T cell immunotherapy

(2019) Alexandre V. Hirayama et al.   AMERICAN JOURNAL OF HEMATOLOGY

Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma

(2019) Jennifer L. Crombie et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

CD19 CAR T cell product and disease attributes predict leukemia remission durability

(2019) Olivia C. Finney et al.   JOURNAL OF CLINICAL INVESTIGATION

TOX is a critical regulator of tumour-specific T cell differentiation

(2019) Andrew C. Scott et al.   NATURE

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

(2019) Omar Khan et al.   NATURE

The IL ‐6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B‐cell lymphoma

(2019) Hind Hashwah et al.   EMBO Molecular Medicine

Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

(2018) Xinyi Guo et al.   NATURE MEDICINE

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

(2018) Theodoros Giavridis et al.   NATURE MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

(2018) Robert Q. Le et al.   ONCOLOGIST

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma

(2018) Li Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The promise of CAR T-cell therapy in aggressive B-cell lymphoma

(2018) Ranjit Nair et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME)

(2018) John M. Rossi et al.   Clinical Lymphoma Myeloma & Leukemia

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

(2018) Rosalie M. Sterner et al.   BLOOD

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

(2018) Jennifer N. Brudno et al.   BLOOD REVIEWS

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

CD19-directed CAR T cells gain traction

(2018) Stephen J Schuster   LANCET ONCOLOGY

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

(2018) Michael M. Boyiadzis et al.   Journal for ImmunoTherapy of Cancer

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

(2017) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

B cell–derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity

(2017) Tanvi Arkatkar et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL

(2017) Zachary J. Roberts et al.   LEUKEMIA & LYMPHOMA

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

(2017) Frederick L. Locke et al.   MOLECULAR THERAPY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Chimeric antigen receptor T-cell therapies for lymphoma

(2017) Jennifer N. Brudno et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

(2017) Russell W. Jenkins et al.   Cancer Discovery

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

(2016) Elise A. Chong et al.   BLOOD

CXCR4 and CCR7: Two eligible targets in targeted cancer therapy

(2016) Mohammad Amir Mishan et al.   CELL BIOLOGY INTERNATIONAL

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

(2016) M. Ruella et al.   CLINICAL CANCER RESEARCH

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

(2016) Cameron J. Turtle et al.   Science Translational Medicine

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

(2014) Saar Gill et al.   IMMUNOLOGICAL REVIEWS

Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis

(2014) Edward C. Stack et al.   METHODS

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

New developments in the management of diffuse large B-cell lymphoma

(2012) Habermann   Hematology

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD